Galapagos and Janssen part ways following 'therapeutic shift'

Galapagos, which said in December that its partnership with Janssen Pharmaceutica was "very much alive," now says the companies have agreed to mutually terminate their inflammation alliance and option agreements. "The therapeutic indications of these programs have shifted along the way and moved outside focus areas of Janssen," Galapagos CEO Onno van de Stolpe told Scrip.

Galapagos, which said in December that its partnership with Janssen Pharmaceutica was "very much alive," now says the companies have agreed to mutually terminate their inflammation alliance and option agreements. "The therapeutic indications of these programs have shifted along the way and moved outside focus areas of Janssen," Galapagos CEO Onno van de Stolpe told Scrip.

Among others, all rights to candidate drug GLPG1690, a selective autotaxin inhibitor, have been returned to Galapagos. A first-in-human Phase...

More from Musculoskeletal

Biogen’s Spinraza Follow-On May Offer Disease-Modifying Potential

 
• By 

Biogen hopes to move directly from Phase I to Phase III with salanersen, a higher-potency therapy that uses the same mechanism of action as Spinraza.

Lilly’s Muscle Builder Looks Strong In GLP-1 Obesity Combo

 

Bimagrumab added to Wegovy increased weight loss and preserved muscle mass, but analysts want to see more safety and efficacy results from a combination with Zepbound.

Sarepta Market Dynamics For Elevidys Imperiled By Second Patient Death

 
• By 

With two deaths in non-ambulatory DMD patients, Sarepta is attempting damage control and will ask the US FDA to advise, setting up a possible confrontation with CBER director Prasad.

Lilly Looks For Muscle-Sparing Candidates In Pact With Juvena

 
• By 

Deal Snapshot: Including its internal efforts with bimagrumab, Lilly has been seeking a muscle-sparing therapy to complement GLP-1 obesity drugs, such as Zepbound.

More from Therapy Areas

Could Apogee Rival Regeneron/Sanofi, Lilly After Phase II Eczema Data Win?

 
• By 

Apogee Therapeutics reports data from Phase II APEX trial of its long-acting antibody against atopic dermatitis, showing similar efficacy to Regeneron/Sanofi’s Dupixent and Eli Lilly’s Ebglyss.

Cogent Peaks With Bezaclastinib SUMMIT Results

 

The biotech announced positive topline results from the Phase II SUMMIT study in non-advanced systemic mastocytosis, with data for advanced SM and GIST expected later this year.

France’s AB Science Plots Pivotal Masitinib Trial In Prostate Cancer

 
• By 

Still holding out hope after multiple rejections for the tyrosine kinase inhibitor.